Nifty
Sensex
:
:
24406.10
80039.80
-7.40 (-0.03%)
-109.08 (-0.14%)

Pharmaceuticals & Drugs - Global

Rating :
69/99

BSE: 524404 | NSE: MARKSANS

187.99
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  164.00
  •  189.25
  •  164.00
  •  166.04
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  17455116
  •  31946.95
  •  207.55
  •  97.45

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 9,305.72
  • 29.66
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 8,661.23
  • 0.29%
  • 4.51

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 43.87%
  • 1.50%
  • 29.47%
  • FII
  • DII
  • Others
  • 18.59%
  • 2.82%
  • 3.75%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.39
  • 13.12
  • 10.41

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.53
  • 20.76
  • -0.02

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.99
  • 28.35
  • 4.12

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.43
  • 12.26
  • 14.12

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.73
  • 2.46
  • 2.56

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.61
  • 8.19
  • 8.85

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
560.01
485.98
15.23%
586.13
479.83
22.15%
531.24
452.56
17.39%
500.03
433.77
15.28%
Expenses
450.37
376.43
19.64%
453.11
403.19
12.38%
417.29
372.30
12.08%
398.07
360.91
10.30%
EBITDA
109.64
109.55
0.08%
133.02
76.64
73.56%
113.95
80.27
41.96%
101.97
72.86
39.95%
EBIDTM
19.58%
22.54%
22.70%
15.97%
21.45%
17.74%
20.39%
16.80%
Other Income
16.53
11.01
50.14%
4.80
17.65
-72.80%
19.00
14.15
34.28%
10.10
16.50
-38.79%
Interest
4.84
2.44
98.36%
3.16
2.35
34.47%
1.63
2.54
-35.83%
1.58
1.80
-12.22%
Depreciation
21.05
13.94
51.00%
22.00
12.74
72.68%
17.55
14.05
24.91%
13.66
11.12
22.84%
PBT
100.28
104.17
-3.73%
112.66
79.20
42.25%
113.77
77.83
46.18%
96.83
76.45
26.66%
Tax
22.63
21.46
5.45%
29.69
16.90
75.68%
29.92
17.71
68.94%
26.39
16.26
62.30%
PAT
77.64
82.71
-6.13%
82.97
62.31
33.16%
83.85
60.12
39.47%
70.44
60.18
17.05%
PATM
13.86%
17.02%
14.15%
12.98%
15.78%
13.28%
14.09%
13.87%
EPS
1.73
1.81
-4.42%
1.84
1.57
17.20%
1.84
1.52
21.05%
1.52
1.46
4.11%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
2,177.41
1,852.14
1,490.84
1,376.18
1,134.21
1,000.07
912.69
767.16
893.33
796.69
630.00
Net Sales Growth
17.56%
24.23%
8.33%
21.33%
13.41%
9.57%
18.97%
-14.12%
12.13%
26.46%
 
Cost Of Goods Sold
1,038.12
921.36
716.81
595.05
567.83
498.01
523.13
458.74
509.69
445.44
367.93
Gross Profit
1,139.29
930.78
774.02
781.13
566.38
502.07
389.57
308.42
383.63
351.25
262.07
GP Margin
52.32%
50.25%
51.92%
56.76%
49.94%
50.20%
42.68%
40.20%
42.94%
44.09%
41.60%
Total Expenditure
1,718.84
1,512.82
1,231.96
1,036.58
941.96
867.92
834.31
734.24
760.91
620.86
516.04
Power & Fuel Cost
-
24.50
18.59
16.42
14.38
14.34
11.83
13.27
12.58
9.72
7.80
% Of Sales
-
1.32%
1.25%
1.19%
1.27%
1.43%
1.30%
1.73%
1.41%
1.22%
1.24%
Employee Cost
-
239.37
220.30
197.32
168.42
159.07
147.75
149.70
122.42
72.61
66.44
% Of Sales
-
12.92%
14.78%
14.34%
14.85%
15.91%
16.19%
19.51%
13.70%
9.11%
10.55%
Manufacturing Exp.
-
18.73
12.73
127.47
113.32
77.14
59.90
47.34
50.44
37.59
30.11
% Of Sales
-
1.01%
0.85%
9.26%
9.99%
7.71%
6.56%
6.17%
5.65%
4.72%
4.78%
General & Admin Exp.
-
52.58
37.74
50.67
45.52
51.03
42.51
37.52
36.01
15.35
16.13
% Of Sales
-
2.84%
2.53%
3.68%
4.01%
5.10%
4.66%
4.89%
4.03%
1.93%
2.56%
Selling & Distn. Exp.
-
102.53
119.05
33.54
32.15
68.36
49.14
27.66
29.77
34.47
27.63
% Of Sales
-
5.54%
7.99%
2.44%
2.83%
6.84%
5.38%
3.61%
3.33%
4.33%
4.39%
Miscellaneous Exp.
-
153.75
106.73
16.10
0.34
-0.01
0.05
0.00
0.00
5.67
27.63
% Of Sales
-
8.30%
7.16%
1.17%
0.03%
0.00%
0.01%
0%
0%
0.71%
0%
EBITDA
458.58
339.32
258.88
339.60
192.25
132.15
78.38
32.92
132.42
175.83
113.96
EBITDA Margin
21.06%
18.32%
17.36%
24.68%
16.95%
13.21%
8.59%
4.29%
14.82%
22.07%
18.09%
Other Income
50.43
59.31
41.85
6.69
0.33
4.62
8.47
18.85
12.72
12.23
7.28
Interest
11.21
9.13
8.45
7.99
8.75
9.66
10.22
6.78
10.16
16.05
19.13
Depreciation
74.26
51.85
44.78
36.15
26.66
22.80
26.84
30.09
28.13
16.13
15.69
PBT
423.54
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
155.88
86.41
Tax
108.63
72.33
60.70
63.63
36.42
23.87
14.00
3.56
24.11
43.92
12.79
Tax Rate
25.65%
21.42%
24.52%
21.06%
23.17%
22.88%
28.11%
23.89%
22.56%
28.18%
14.80%
PAT
314.90
266.31
184.56
235.94
117.02
76.46
32.94
8.83
78.51
109.39
71.90
PAT before Minority Interest
313.71
265.32
186.81
238.54
120.75
80.44
35.80
11.33
82.74
111.96
73.62
Minority Interest
-1.19
0.99
-2.25
-2.60
-3.73
-3.98
-2.86
-2.50
-4.23
-2.57
-1.72
PAT Margin
14.46%
14.38%
12.38%
17.14%
10.32%
7.65%
3.61%
1.15%
8.79%
13.73%
11.41%
PAT Growth
18.69%
44.29%
-21.78%
101.62%
53.05%
132.12%
273.05%
-88.75%
-28.23%
52.14%
 
EPS
6.95
5.88
4.07
5.21
2.58
1.69
0.73
0.19
1.73
2.41
1.59

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
1,745.16
1,202.27
886.50
636.01
542.48
470.86
433.43
454.32
379.76
142.18
Share Capital
45.32
40.93
40.93
40.93
40.93
40.93
40.93
53.43
53.43
52.03
Total Reserves
1,699.85
1,068.24
845.56
595.08
501.55
429.93
392.50
400.89
326.33
90.15
Non-Current Liabilities
93.81
57.05
23.70
24.15
17.14
15.64
16.07
-1.91
1.46
22.16
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
19.82
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
12.74
1.86
2.11
1.47
1.36
1.08
0.96
0.00
0.00
0.00
Current Liabilities
365.36
380.08
298.97
228.75
232.62
234.68
296.06
259.43
286.24
319.12
Trade Payables
230.60
200.08
168.66
110.33
106.07
77.83
161.78
118.98
107.02
83.18
Other Current Liabilities
42.20
96.80
79.69
58.86
20.90
10.08
0.71
0.68
39.88
96.58
Short Term Borrowings
41.59
41.29
18.74
18.84
99.91
117.41
109.71
87.89
82.19
105.54
Short Term Provisions
50.97
41.92
31.88
40.72
5.74
29.36
23.85
51.88
57.15
33.82
Total Liabilities
2,224.24
1,660.10
1,228.03
902.02
802.46
730.73
751.81
720.20
675.56
490.10
Net Block
486.31
428.31
309.36
302.72
269.73
279.38
266.98
269.65
165.90
145.65
Gross Block
828.26
726.26
551.92
565.39
506.26
495.35
456.49
429.47
297.78
261.70
Accumulated Depreciation
341.95
297.96
242.56
262.67
236.54
215.97
189.52
159.82
131.89
116.05
Non Current Assets
524.57
435.04
325.20
308.45
271.02
280.19
267.92
280.06
166.72
147.15
Capital Work in Progress
9.87
2.57
11.68
0.00
0.00
0.00
0.36
0.00
0.00
0.00
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
28.40
4.16
4.16
5.73
1.29
0.82
0.59
10.41
0.83
1.50
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,699.67
1,225.07
902.82
593.59
531.44
450.54
483.88
440.15
508.83
342.95
Current Investments
0.54
0.44
0.26
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
484.74
424.44
404.32
241.84
293.25
218.12
190.09
167.79
130.11
102.59
Sundry Debtors
416.85
394.78
271.95
243.35
176.60
176.91
247.58
217.29
183.45
169.61
Cash & Bank
714.96
349.26
212.18
93.73
33.54
39.88
25.16
35.30
185.27
46.95
Other Current Assets
82.58
24.36
14.11
11.26
28.06
15.63
21.05
19.76
10.01
23.80
Short Term Loans & Adv.
59.84
31.79
0.00
3.40
0.00
0.00
20.96
19.76
10.01
23.80
Net Current Assets
1,334.31
844.98
603.85
364.83
298.82
215.86
187.82
180.71
222.60
23.83
Total Assets
2,224.24
1,660.11
1,228.02
902.04
802.46
730.73
751.80
720.21
675.55
490.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
237.41
99.26
178.59
233.33
27.40
50.09
14.06
30.80
154.51
64.84
PBT
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
109.40
71.91
Adjustment
74.24
35.31
56.57
42.04
31.88
43.99
26.58
39.63
24.26
19.57
Changes in Working Capital
-111.47
-110.70
-131.61
59.12
-81.79
-36.23
-6.04
-88.14
20.27
-26.01
Cash after chg. in Working capital
300.43
172.12
227.12
258.33
54.40
57.56
35.44
58.34
153.94
65.47
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-63.01
-72.86
-48.53
-25.00
-27.00
-7.46
-21.37
-27.54
-0.89
-0.27
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-259.21
-84.39
-44.85
-59.58
-13.48
-38.81
-20.73
-123.01
-33.19
-4.49
Net Fixed Assets
-21.45
-24.09
-28.48
-23.87
-23.07
-5.86
-11.49
-22.01
-32.23
-2.62
Net Investments
-29.78
-0.18
-0.26
0.00
0.00
-1.78
-2.85
-163.82
0.00
0.00
Others
-207.98
-60.12
-16.11
-35.71
9.59
-31.17
-6.39
62.82
-0.96
-1.87
Cash from Financing Activity
197.83
79.51
-15.29
-113.55
-20.78
3.38
-3.47
-57.75
16.99
-29.28
Net Cash Inflow / Outflow
176.03
94.38
118.46
60.19
-6.86
14.67
-10.14
-149.96
138.32
31.07
Opening Cash & Equivalents
206.41
112.03
93.73
33.54
39.72
25.05
35.30
185.27
46.95
15.88
Closing Cash & Equivalent
382.44
206.41
212.18
93.73
32.85
39.72
25.16
35.30
185.27
46.95

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
38.51
27.10
21.66
15.54
13.25
11.50
10.59
10.79
8.97
3.34
ROA
13.66%
12.94%
22.40%
14.17%
10.49%
4.83%
1.54%
11.86%
19.21%
16.52%
ROE
18.59%
18.72%
31.33%
20.49%
15.88%
7.92%
2.59%
20.45%
45.15%
73.02%
ROCE
22.89%
23.82%
39.76%
25.57%
18.51%
10.60%
3.99%
23.16%
44.64%
38.30%
Fixed Asset Turnover
2.62
2.42
2.49
2.12
2.00
1.92
1.73
2.46
2.85
2.43
Receivable days
72.63
78.56
67.57
67.57
64.51
84.88
110.59
81.87
80.88
87.17
Inventory Days
81.36
97.65
84.73
86.10
93.32
81.63
85.14
60.86
53.30
52.22
Payable days
85.31
93.88
85.57
45.09
38.48
55.10
65.56
54.58
56.06
48.85
Cash Conversion Cycle
68.67
82.33
66.73
108.58
119.35
111.40
130.17
88.15
78.13
90.54
Total Debt/Equity
0.02
0.04
0.02
0.03
0.18
0.25
0.25
0.19
0.23
1.12
Interest Cover
37.99
30.31
38.84
18.97
11.80
5.87
3.20
11.52
10.72
5.52

News Update:


  • Marksans Pharma’s arm gets marketing authorization for four products
    2nd Jul 2024, 18:15 PM

    The company’s arm has received marketing Authorization from UKMHRA

    Read More
  • Marksans Pharma reports 6% fall in Q4 consolidated net profit
    30th May 2024, 15:45 PM

    Total consolidated income of the company increased by 16.01% at Rs 576.54 crore for Q4FY24

    Read More
  • Marksans Pharma - Quarterly Results
    30th May 2024, 12:05 PM

    Read More
  • Marksans Pharma’s arm gets Marketing Authorisation for Levetiracetam Relonchem Oral Solution
    28th May 2024, 12:24 PM

    The product will be manufactured at the Group’s UK manufacturing facility

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.